606 reports of this reaction
2.3% of all VALSARTAN AND HYDROCHLOROTHIAZIDE reports
#8 most reported adverse reaction
DYSPNOEA is the #8 most commonly reported adverse reaction for VALSARTAN AND HYDROCHLOROTHIAZIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 606 FDA adverse event reports linking VALSARTAN AND HYDROCHLOROTHIAZIDE to DYSPNOEA. This represents approximately 2.3% of all 26,234 adverse event reports for this drug.
Patients taking VALSARTAN AND HYDROCHLOROTHIAZIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for VALSARTAN AND HYDROCHLOROTHIAZIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for VALSARTAN AND HYDROCHLOROTHIAZIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 606 FDA reports for VALSARTAN AND HYDROCHLOROTHIAZIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.3% of all adverse event reports for VALSARTAN AND HYDROCHLOROTHIAZIDE, making it a notable side effect.
If you experience dyspnoea while taking VALSARTAN AND HYDROCHLOROTHIAZIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.